PCSK9 Inhibitors: What Do Cardiologists Think?
This article was originally published in Scrip
Cardiologists appear confident of both the efficacy and safety of the new PCSK9 inhibitors, even ahead of their cardiovascular outcomes trial (CVOT) data, a new survey by BioMedTracker has found.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.